skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Management of diabetes across the course of disease: minimizing obesity-associated complications

Review

(1733) Views  (839) Full article downloads

Authors: Apovian CM

Published Date October 2011 Volume 2011:4 Pages 353 - 369
DOI: http://dx.doi.org/10.2147/DMSO.S24022

Caroline M Apovian
Medicine and Pediatrics, Boston University School of Medicine; Nutrition and Weight Management Center; and Section of Endocrinology, Diabetes and Nutrition, Department of Medicine, Boston Medical Center, Boston, MA, USA

Abstract: Obesity increases the risk for developing type 2 diabetes mellitus (T2DM) and this in turn correlates with an elevated probability of long-term diabetes complications once diabetes is established. Interventions aimed at lowering weight via changes in diet and lifestyle have repeatedly been shown to improve glycemic control in patients with T2DM and even to reverse early disease. Weight gain, a potential side effect of treatment for patients with T2DM, is also an important concern, and it has been noted that weight increases associated with antidiabetes therapy may blunt cardiovascular risk reductions achieved by decreasing blood glucose. Among older agents, metformin and acarbose have the lowest risk for weight gain, while sulfonylureas, meglitinides, and thiazolidinediones are all associated with weight increases. Clinical trial results have also consistently demonstrated that treatment with glucagon-like peptide-1 receptor agonists and amylin lowers weight, and that dipeptidyl peptidase-4 inhibitors are weight neutral in patients with T2DM. Conventional human insulin formulations are known to increase weight in patients with T2DM. However, some insulin analogs, particularly insulin detemir, have lower liability for this adverse event. The use of both pharmacologic and surgical therapies aimed at treating obesity rather than lowering blood glucose have the potential to improve glycemic control and even resolve T2DM in some patients.

Keywords: bariatric, diabetes, incretin, insulin, obesity, oral antidiabetes agents







Readers of this article also read:

The route to diabetes: Loss of complexity in the glycemic profile from health through the metabolic syndrome to type 2 diabetes
Adipose inflammation: cause or consequence of obesity-related insulin resistance
Comorbidity and glycemia control among patients with type 2 diabetes in primary care
Predictors of weight loss and maintenance in patients treated with antiobesity drugs
Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Clinical and behavioral factors associated with management outcome in hospitalized patients with diabetic foot ulcer
The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis
Insulin detemir for the treatment of obese patients with type 2 diabetes
Association between diabetes complications and leukocyte counts in Iranian patients
Obesity: considerations about etiology, metabolism, and the use of experimental models
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio